GT Biopharma (NASDAQ:GTBP) Shares to Reverse Split on Tuesday, September 8th

Shares of GT Biopharma, Inc. (NASDAQ:GTBP) are scheduled to reverse split on Tuesday, September 8th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 7th.

GT Biopharma Stock Down 4.5%

GT Biopharma stock traded down $0.01 during mid-day trading on Friday, hitting $0.24. 1,158,788 shares of the company’s stock traded hands, compared to its average volume of 448,466. The firm has a 50 day moving average price of $0.34 and a 200 day moving average price of $0.39. The company has a market cap of $10.87 million, a PE ratio of -0.04 and a beta of 0.91. GT Biopharma has a one year low of $0.22 and a one year high of $1.37.

GT Biopharma (NASDAQ:GTBP) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.04). On average, analysts expect that GT Biopharma will post -0.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

GTBP has been the subject of several research analyst reports. Wall Street Zen upgraded GT Biopharma to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GT Biopharma in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On GT Biopharma

A hedge fund recently bought a new stake in GT Biopharma stock. 49 Wealth Management LLC acquired a new position in GT Biopharma, Inc. (NASDAQ:GTBP) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 64,000 shares of the company’s stock, valued at approximately $31,000. 49 Wealth Management LLC owned about 0.14% of GT Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).